Understanding the role of RNA-binding protein NONO and its long non-coding RNA target NEAT1 in driving progression of neuroblastoma

Alina Naveed

Research output: ThesisDoctoral Thesis

307 Downloads (Pure)

Abstract

Neuroblastoma is the most common infant cancer, and new therapies are required for aggressive subtypes. Existing neuroblastoma therapeutics cause therapy-related toxicity, impairing patients? quality of life. NONO RNA-binding protein
was found to have an oncogenic role, whereas its long noncoding RNA binding target NEAT1 was found to have a tumour-suppressor role in high-risk neuroblastoma. NEAT1-promoting antisense oligonucleotide therapeutics were developed to inhibit neuroblastoma cell growth. NONO reduction experiments showed that NONO promotes cancer cell metabolism. Investigation of the NONO and NEAT1 molecules in neuroblastoma has led to the generation of RNA therapeutics that hold the potential to treat neuroblastoma patients.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • The University of Western Australia
Supervisors/Advisors
  • Fox, Archa, Supervisor
  • Bond, Charlie, Supervisor
  • Forrest, Alistair, Supervisor
  • Choi, Yu Suk, Supervisor
Award date6 Aug 2020
DOIs
Publication statusUnpublished - 2020

Fingerprint Dive into the research topics of 'Understanding the role of RNA-binding protein NONO and its long non-coding RNA target NEAT1 in driving progression of neuroblastoma'. Together they form a unique fingerprint.

Cite this